EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in Neovascular Age-Related Macular Degeneration in Subgroups Defined by Baseline Characteristics

Richard P Gale, Anat Loewenstein, Xin Zhang, Sergio Leal, Tobias Machewitz, Sobha Sivaprasad, David T Wong, Oliver Zeitz, Jean-François Korobelnik, PULSAR study investigators

Ophthalmology Retina · 2026

DOI: 10.1016/j.oret.2026.02.020 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Ophthalmology Retina, 2026. Verfasst von Richard P Gale und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hull York Medical School, University of York, and York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Visual Acuity, Wet Macular Degeneration. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVisual AcuityWet Macular DegenerationAgedFemaleHumansMaleAngiogenesis InhibitorsDose-Response Relationship, DrugDouble-Blind MethodFluorescein AngiographyFollow-Up StudiesFundus OculiIntravitreal InjectionsTomography, Optical CoherenceTreatment Outcome

Stichwörter der Autor:innen

Aflibercept 8 mgBaseline disease severityExtended dosing intervalsNeovascular age-related macular degenerationPULSAR.

Substanzen

afliberceptAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Hull York Medical School, University of York, and York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK.
  • Ophthalmology Division, Tel Aviv Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Bayer Consumer Care AG, Basel, Switzerland.
  • Bayer AG, Berlin, Germany.
  • NiHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK. Electronic address: senswathi@aol.com.
  • Department of Ophthalmology and Vision Sciences, University of Toronto and Unity Health Toronto, St. Michael's Hospital, Toronto, Ontario, Canada.

Förderung

  • Regeneron Pharmaceuticals Inc
  • Bayer

Zitieren

APA

Gale, R. P., Loewenstein, A., Zhang, X., Leal, S., Machewitz, T., Sivaprasad, S., Wong, D. T., Zeitz, O., Korobelnik, J. F., & PULSAR study investigators (2026). PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in Neovascular Age-Related Macular Degeneration in Subgroups Defined by Baseline Characteristics. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2026.02.020

Vancouver

Gale RP, Loewenstein A, Zhang X, Leal S, Machewitz T, Sivaprasad S, et al. PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in Neovascular Age-Related Macular Degeneration in Subgroups Defined by Baseline Characteristics. Ophthalmology Retina. 2026. doi:10.1016/j.oret.2026.02.020

BibTeX
@article{Gale2026,
  author = {Gale, Richard P and Loewenstein, Anat and Zhang, Xin and Leal, Sergio and Machewitz, Tobias and Sivaprasad, Sobha and Wong, David T and Zeitz, Oliver and Korobelnik, Jean-François and PULSAR study investigators, PULSAR study investigators},
  title = {PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in Neovascular Age-Related Macular Degeneration in Subgroups Defined by Baseline Characteristics},
  journal = {Ophthalmology Retina},
  year = {2026},
  doi = {10.1016/j.oret.2026.02.020}
}
Kostenlos starten →